🧾 What This Document Is

This is an 8-K filing, which is like a company's "major news bulletin" for the stock market. Omeros is using it to report its financial results for the last quarter and full year of 2025, and more importantly, to announce some huge company-making news. You'll get the numbers, but also the story behind them: a major drug approval, a big partnership deal, and what it all means going forward.

🏢 What The Company Does

👉 In simple terms, Omeros is a biotech company that invents new drugs for tough diseases. They focus on three main areas: diseases caused by the immune system's "complement" system (like rare blood disorders), cancer, and addictive disorders like cocaine use. They just took a giant leap from being a research-focused company to becoming a commercial one with an FDA-approved drug on the market.

💰 Financial Highlights: A Tale of Two Numbers

The headlines show a wild swing: a massive profit in Q4, but a small loss for the full year. Here’s why it’s confusing, and what it really means.

• Q4 2025 Net Income: $86.5 million (profit!), or $1.22 per share. This is a huge turnaround from a $31.4 million loss in Q4 2024.
• Full Year 2025 Net Loss: $3.4 million, or $0.05 per share. This is vastly better than the $156.8 million loss in 2024.

👉 Why it matters: The Q4 profit is almost entirely due to a one-time event: selling the rights to their drug zaltenibart to Novo Nordisk for a big upfront payment. If you strip out that big gain and another complex, non-cash accounting charge, the company says its "adjusted" profit for the year was actually a healthy $133.4 million. The core operational loss is shrinking dramatically.

🚀 Key Moves: The Novo Nordisk Deal

This was the transformative event of the quarter. On November 25, 2025, Omeros sold the global rights to its drug zaltenibart to the pharmaceutical giant Novo Nordisk.

• What they got: An immediate $240 million in cash. They could also earn up to $1.8 billion more in future milestone payments, plus royalties on sales if the drug succeeds.
• What they kept: The rights to develop other related, non-zaltenibart drugs in the same class (MASP-3 inhibitors).
• What they did with the cash: They immediately used a big chunk to pay off $67.1 million in debt from a term loan. They later paid off another $17.1 million in convertible notes.

👉 Why it matters: This deal was a massive win. It provided a huge cash infusion to fund operations, wiped out a significant chunk of debt, and validated their science with a partner like Novo Nordisk. It also lets Omeros focus on its other programs.

📦 New Revenue Engine: YARTEMLEA® Approval & Launch

The other blockbuster news: On December 23, 2025, the FDA approved YARTEMLEA®.

• What it treats: A rare and often fatal complication called TA-TMA in patients who have had stem cell transplants.
• Why it's a big deal: It's the first and only approved therapy for this condition. It works very selectively, which might mean fewer side effects.
• Status: Commercial sales started in January 2026. Omeros has its sales team in place and is already getting the drug to patients. A European approval decision is expected in mid-2026.

👉 Why it matters: This is Omeros's first own commercial product. Success here provides a new, ongoing revenue stream to fund the company long-term, moving them from burning cash to hopefully generating it.

🔮 What's Next: The Pipeline & Path to Profit

With cash in hand and a product launched, Omeros is looking to grow. They have several "shots on goal" in development:

• OncotoX-AML: A promising new cancer drug for acute myeloid leukemia (AML) that has shown strong results in primate studies. IND-enabling studies are underway.
• T-CAT: A new class of antibodies designed to kill drug-resistant bacteria (MDROs), a major global health threat. Animal data is accumulating, and a scientific publication is expected soon.
• OMS527: A cocaine use disorder treatment fully funded by a government grant. They are working with the FDA to start a clinical trial.

👉 The Big Goal: The CEO stated they are targeting positive cash flow in 2027, fueled by YARTEMLEA sales and this pipeline.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Transformative Deal: The Novo Nordisk partnership provided crucial cash and debt reduction.
• First Commercial Product: YARTEMLEA is approved and launched, creating real revenue.
• Clean Balance Sheet: Debt was cut by 47% in 2025.
• Promising Pipeline: Multiple high-potential programs in oncology and infectious disease.

⚠️ Risks:

• Commercial Execution: Can Omeros successfully launch and grow sales of YARTEMLEA in a competitive market?
• Pipeline Uncertainty: Early-stage drugs (like OncotoX-AML) still face years of testing and risk of failure.
• Reliance on Partners: Future big payments depend on Novo Nordisk's success with zaltenibart.
• Profitability Timeline: The path to consistent, self-funded profit in 2027 is not guaranteed.

🧠 The Analogy

Think of Omeros like a homeowner who owned a valuable piece of land (zaltenibart). They sold it to a wealthy developer (Novo Nordisk) for a large sum of cash. They immediately used that cash to pay off their mortgage (debt). Now, with a newly built house on another lot (YARTEMLEA) finally ready for tenants (patients), and with several promising blueprints for new buildings (pipeline) on the drawing board, they are transitioning from being land-rich-and-cash-poor to becoming a landlord with multiple income streams.

📇 Key Contacts & People

• Investor and Media Contact: Jennifer Cook Williams, Cook Williams Communications, Inc.
• Email: [email protected]
• CEO: Gregory A. Demopulos, M.D.

🧩 Final Takeaway

Omeros just had a transformative quarter. The blockbuster sale of zaltenibart to Novo Nordisk provided a massive cash injection and debt paydown, while the simultaneous FDA approval and launch of its own drug, YARTEMLEA, gives the company its first real commercial revenue stream. The focus now shifts to executing the YARTEMLEA launch and advancing a promising pipeline, with a goal of achieving positive cash flow in 2027.